Literature DB >> 17392174

Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes.

Dita Gratzinger1, Shuchun Zhao, Robert J Marinelli, Amy V Kapp, Robert J Tibshirani, Anne S Hammer, Stephen Hamilton-Dutoit, Yasodha Natkunam.   

Abstract

Angiogenesis is known to play a major role in neoplasia, including hematolymphoid neoplasia. We assessed the relationships among angiogenesis and expression of vascular endothelial growth factor and its receptors in the context of clinically and biologically relevant subtypes of diffuse large B-cell lymphoma using immunohistochemical evaluation of tissue microarrays. We found that diffuse large B-cell lymphoma specimens showing higher local vascular endothelial growth factor expression showed correspondingly higher microvessel density, implying that lymphoma cells induce local tumor angiogenesis. In addition, local vascular endothelial growth factor expression was higher in those specimens showing higher expression of the receptors of the growth factor, suggesting an autocrine growth-promoting feedback loop. The germinal center-like and nongerminal center-like subtypes of diffuse large B-cell lymphoma were biologically and prognostically distinct. Interestingly, only in the more clinically aggressive nongerminal center-like subtype were microvessel densities significantly higher in specimens showing higher vascular endothelial growth factor expression; the same was true for the finding of higher vascular endothelial growth factor receptor-1 expression in conjunction with higher vascular endothelial growth factor expression. These differences may have important implications for the responsiveness of the two diffuse large B-cell lymphoma subtypes to anti-vascular endothelial growth factor and anti-angiogenic therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392174      PMCID: PMC1829468          DOI: 10.2353/ajpath.2007.060901

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  20 in total

1.  Bone marrow angiogenesis and progression in multiple myeloma.

Authors:  A Vacca; D Ribatti; L Roncali; G Ranieri; G Serio; F Silvestris; F Dammacco
Journal:  Br J Haematol       Date:  1994-07       Impact factor: 6.998

2.  TreeView: an application to display phylogenetic trees on personal computers.

Authors:  R D Page
Journal:  Comput Appl Biosci       Date:  1996-08

3.  A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma.

Authors:  P Salven; L Teerenhovi; H Joensuu
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

Review 4.  Angiogenesis in malignant lymphoma.

Authors:  Ad Koster; John M M Raemaekers
Journal:  Curr Opin Oncol       Date:  2005-11       Impact factor: 3.645

5.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.

Authors:  N Weidner; J P Semple; W R Welch; J Folkman
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

6.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

Authors:  J O Armitage; D D Weisenburger
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

7.  Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy.

Authors:  S Kumar; M A Gertz; A Dispenzieri; M Q Lacy; L A Wellik; R Fonseca; J A Lust; T E Witzig; R A Kyle; P R Greipp; S V Rajkumar
Journal:  Bone Marrow Transplant       Date:  2004-08       Impact factor: 5.483

8.  Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo.

Authors:  Eunice S Wang; Julie Teruya-Feldstein; Yan Wu; Zhenping Zhu; Daniel J Hicklin; Malcolm A S Moore
Journal:  Blood       Date:  2004-07-06       Impact factor: 22.113

Review 9.  VEGF-receptor signal transduction.

Authors:  Michael J Cross; Johan Dixelius; Taro Matsumoto; Lena Claesson-Welsh
Journal:  Trends Biochem Sci       Date:  2003-09       Impact factor: 13.807

10.  Tissue microarrays for high-throughput molecular profiling of tumor specimens.

Authors:  J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

View more
  29 in total

1.  A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.

Authors:  Alison T Stopeck; Joseph M Unger; Lisa M Rimsza; William T Bellamy; Maria Iannone; Daniel O Persky; Michael Leblanc; Richard I Fisher; Thomas P Miller
Journal:  Leuk Lymphoma       Date:  2009-05

Review 2.  Image analysis tools for evaluation of microscopic views of immunohistochemically stained specimen in medical research-a review.

Authors:  Keerthana Prasad; Gopalakrishna K Prabhu
Journal:  J Med Syst       Date:  2011-05-17       Impact factor: 4.460

Review 3.  Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2011-09-23       Impact factor: 3.064

4.  A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.

Authors:  Alison T Stopeck; Joseph M Unger; Lisa M Rimsza; Michael LeBlanc; Brent Farnsworth; Maria Iannone; Martha J Glenn; Richard I Fisher; Thomas P Miller
Journal:  Blood       Date:  2012-06-25       Impact factor: 22.113

5.  Angioimmunoblastic T-cell lymphoma: the effect of initial treatment and microvascular density in 31 patients.

Authors:  Shu Zhao; Liangyu Zhang; Minghui Zhang; Guodong Yao; Xiaosan Zhang; Wenhui Zhao; Wei Ren; Jingxuan Wang; Qingyuan Zhang
Journal:  Med Oncol       Date:  2011-10-30       Impact factor: 3.064

6.  Effects of microvascular density on primary pulmonary non-Hodgkin's lymphoma (PPL).

Authors:  Maopeng Yang; Shu Zhao; Xaiosan Zhang; Xiaohong Wang; Minghui Zhang; Yan Wang; Qingyuan Zhang
Journal:  Tumour Biol       Date:  2012-08-09

Review 7.  Role of Wnt canonical pathway in hematological malignancies.

Authors:  Xueling Ge; Xin Wang
Journal:  J Hematol Oncol       Date:  2010-09-15       Impact factor: 17.388

Review 8.  The role of angiogenesis in human non-Hodgkin lymphomas.

Authors:  Domenico Ribatti; Beatrice Nico; Girolamo Ranieri; Giorgina Specchia; Angelo Vacca
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

9.  Lymphangiogenesis in non-Hodgkin's lymphoma and its correlation with cyclooxygenase-2 and vascular endothelial growth factor-C.

Authors:  Shu-Pei Ma; Mei Lin; Hai-Ning Liu; Jian-Xian Yu
Journal:  Oncol Lett       Date:  2012-07-23       Impact factor: 2.967

Review 10.  Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma.

Authors:  J Ruan; K Hajjar; S Rafii; J P Leonard
Journal:  Ann Oncol       Date:  2008-12-16       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.